Xynomic Pharmaceuticals Holdings, Inc. (XYNO): Price and Financial Metrics
XYNO Price/Volume Stats
| Current price | $2.22 | 52-week high | $3.84 |
| Prev. close | $2.16 | 52-week low | $0.20 |
| Day low | $2.22 | Volume | 100 |
| Day high | $2.22 | Avg. volume | 875 |
| 50-day MA | $2.05 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 102.73M |
XYNO Stock Price Chart Interactive Chart >
Xynomic Pharmaceuticals Holdings, Inc. (XYNO) Company Bio
Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.
XYNO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | -36.39% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | -51.57% |
| 2019 | N/A |
Loading social stream, please wait...